JHVEPhoto/iStock Editorial via Getty Images
- Novo Nordisk (NVO) will launch an oral version of its blockbuster weight loss drug Wegovy (semaglutide) — assuming it wins US FDA approval — on telehealth sites, such as WeightWatchers (WW).
- If approved, the pill would launch in early 2026. Novo
